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Abstract
Background: A poor vitamin D status has been associated with a high disease activity of multiple sclerosis (MS). Recently,
we described associations between vitamin D status and peripheral T cell characteristics in relapsing remitting MS (RRMS)
patients. In the present study, we studied the effects of high dose vitamin D3 supplementation on safety and T cell related
outcome measures.
Methodology/Principal Findings: Fifteen RRMS patients were supplemented with 20 000 IU/d vitamin D3 for 12 weeks.
Vitamin D and calcium metabolism were carefully monitored, and T cell characteristics were studied by flowcytometry. All
patients finished the protocol without side-effects, hypercalcaemia, or hypercalciuria. The median vitamin D status increased
from 50 nmol/L (31–175) at week 0 to 380 nmol/L (151–535) at week 12 (P,0.001). During the study, 1 patient experienced
an exacerbation of MS and was censored from the T cell analysis. The proportions of (naı ¨ve and memory) CD4
+ Tregs
remained unaffected. Although Treg suppressive function improved in several subjects, this effect was not significant in the
total cohort (P=0.143). An increased proportion of IL-10
+ CD4
+ T cells was found after supplementation (P=0.021).
Additionally, a decrease of the ratio between IFN-c
+ and IL-4
+ CD4
+ T cells was observed (P=0.035).
Conclusion/Significance: Twelve week supplementation of high dose vitamin D3 in RRMS patients was well tolerated and
did not induce decompensation of calcium metabolism. The skewing towards an anti-inflammatory cytokine profile
supports the evidence on vitamin D as an immune-modulator, and may be used as outcome measure for upcoming
randomized placebo-controlled trials.
Trial Registration: Clinicaltrials.gov NCT00940719
Citation: Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, et al. (2010) Safety and T Cell Modulating Effects of High Dose Vitamin D3
Supplementation in Multiple Sclerosis. PLoS ONE 5(12): e15235. doi:10.1371/journal.pone.0015235
Editor: Derya Unutmaz, New York University, United States of America
Received September 20, 2010; Accepted November 1, 2010; Published December 13, 2010
Copyright:  2010 Smolders et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: Joost Smolders received consultancy fee from Merck Serono, and received funding for travelling from Biogen Idec; Raymond Hupperts
receives on a regular basis consultancy fees from Bayer Schering, Merck Serono, Biogen Idec and TEVA Aventis. This does not alter the authors’ adherence to all
the PLoS One policies on sharing data and materials.
* E-mail: j.smolders@mumc.nl
Introduction
Multiple Sclerosis (MS) is an inflammatory disease of the central
nervous system, probably of autoimmune origin. It is presumed to
arise from a combination of genetic and environmental factors [1].
One of the environmental factors which gained much attention
during the last decades, is vitamin D. A poor exposure to either
vitamin D or sunlight, its most important inducer, has been
associated with a high risk of developing MS [2]. The underlying
mechanism has not been unravelled yet, but a central role for the
actions of vitamin D on immune regulation has been proposed
[3,4]. The biologically active metabolite of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D), has potent immune modulat-
ing properties, both in vitro and in the experimental animal model
of MS, Experimental Autoimmune Encephalomyelitis (EAE) [5,6].
In vitro, exposure to 1,25(OH)2D inhibits CD4
+ T cell proliferation
and pro-inflammatory cytokine production (IFN-c and IL-17), and
promotes anti-inflammatory cytokine production (IL-4 and IL-10)
and acquisition of regulatory T cell (Treg) phenotype [4].
Not only incidence, but also disease activity of MS has been
associated with vitamin D status. Disability of MS is inversely
correlated with vitamin D status [7,8], but the causality of this
association is uncertain [9]. Additionally, a poor vitamin D status
has been associated with an increased risk on relapses [7,10,11]. A
recent study suggested an increased proportion of relapse free
relapsing remitting MS (RRMS) patients in a cohort supplemented
with <10 000 IU vitamin D3/d for 52 weeks [12]. The immune
modulating properties of vitamin D have been proposed to
underlie these associations. Supplementation of 1 000 IU vitamin
D3/d for 6 months induced elevated circulating TGF-b levels in
MS patients [13]. We studied the correlation of vitamin D status
with T cell regulatory status in a cross-sectional design [14].
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+
Treg were found, vitamin D status correlated positively with the
suppressive capacity of Treg. Additionally, the ratio between pro-
inflammatory IFN-c
+ and anti-inflammatory IL-4
+ CD4
+ T cells
was higher in RRMS patients with a poor vitamin D status. These
associations were independent from the effects of vitamin D on
calcium homeostasis [15].
These clinical observations and experimental data on vitamin D
and MS warrant the development of well designed clinical trials to
assess the disease and immune modulating effects of vitamin D in
MS. The aim of the present study was to explore the safety and the
in vivo effects on the peripheral T cell compartment of high dose
vitamin D3 supplementation in MS.
Materials and Methods
Subjects
Between October – December 2009, 15 RRMS patients were
enrolled [16]. Inclusion criteria were age .18 years, disease
duration ,6 years, use of Beta Interferon (IFN-b) 1a or 1b, and
being relapse free $6 weeks prior to enrolment. Exclusion criteria
were current use of drugs associated with an increased suscep-
tibility to hypercalcaemia, treatment with immune modulating/
suppressive drugs other than IFN-b #6 weeks prior to enrolment,
pregnancy, hypercalcaemia, serum creatinine .100 mmol/L, and
a history of primary hyperparathyroidism, hypercalcaemia, renal
dysfunction, cardiac disease, malignancy, or granulomatous
disease. Holidays to sunny locations and the use of solariums
were not allowed. Continuation of multivitamins containing
vitamin D#600 IU mg/day was allowed. Written informed
consent was obtained from each subject. The regional ethical
committee ‘Atrium-Orbis-Zuyd’ and the institutional ‘Advisory
Board on Scientific Research’ approved this study. This study is
registered at www.clinicaltrials.gov as NCT00940719. The
protocol for this trial is available as supporting information; see
Protocol S1.
Vitamin D3 supplementation
To achieve serum 25-hydroxyvitamin D (25(OH)D) levels
comparable to the study by Burton et al. within 12 weeks [12],
participants were supplemented with 20 000 IU vitamin D3/d. An
oil-based vitamin D3 solution in a concentration of 20 000 IU/mL
was obtained (Vigantol Oil; Merck Serono, Darmstad, Germany)
and patients were instructed to ingest 1 mL each morning [17].
No dose-escalation was incorporated, no dietary restrictions were
imposed, and no additional calcium supplementation was
provided. Vitamin D3 solution was provided twice for 6 weeks.
At the end of week 6 and 12, residual volume of the vitamin D3
solution was assessed. Additionally, patients registered their
vitamin D3 intake daily on a calendar. As a safety follow-up, a
visit was performed at week 16. To further investigate safety, we
added an additional visit at week 24 to the protocol.
Biochemical analysis
At each study visit, calcium, albumin, and 25(OH)D were
measured. Additionally, we periodically measured parathyroid
hormone (PTH), creatinine, urea, electrolytes and liver function
enzymes [alanine transaminase (ALT), aspartate transaminase
(AST), and alkaline phosphatase (ALP)]. Additionally to the
original protocol, a urine sample was obtained the morning of the
study visits on week 12 and 24, to determine the ratio between the
molar concentrations of calcium and creatinine. We measured
PTH on the Immunolite 2500analyzer (Siemens Healthcare
Diagnostics, Deerfield, IL, USA). Other serum and urine
biochemical analytes were measured on the Beckman DXC880i
analyzer (Beckman Coulter, Woerden, The Netherlands). A
radioimmunoassay kit (Immunodiagnostic Systems, Boldon, UK)
was used to measure serum 25(OH)D and 1,25(OH)2D concen-
trations. Toxicity of vitamin D3 manifests as hypercalcemia (serum
total calcium $2.6 mmol/L) or hypercalciuria (urinary calcium to
creatinine ratio .1.0 mmol/L x (mmol/L)
21) [18].
Cell isolation and purification
Cell isolation was performed as described before [14]. PBMC
were isolated by Ficoll gradient centrifugation (Histopaque;
Sigma Aldrich, Zwijndrecht, The Netherlands). CD4
+ T cells
were isolated by negative selection with RosetteSep (Stem
Cell Technologies, Grenoble, France). CD4
+ T cells were
incubated at 4uC for 30 minutes with anti-CD4-APC (Biolegend,
Uithoorn, The Netherlands, #300514), anti-CD25-PE (BD
Biosciences, Breda, The Netherlands, #555432) and anti-
CD127-FITC (E-Bioscience, Hatfield, UK, #11-1278). Human
CD4
+CD25
+CD127
2 Treg [19], and CD4
+CD25
2 responder T
cells (Tresp) were sorted on a FacsAria (BD Biosciences) cell sorter.
After the sort, the median proportion CD4
+CD25
+CD127
2 cells
of all events was 98.9% (97.6–99.5) in the Treg tube, and the
median proportion CD4
+CD25
2 cells was 99.1% (91.0–99.6) in
the Tresp tube. Accessory cells were obtained by irradiating
autologous PBMC with 66.2 gray.
Proliferation suppression assay
The CFSE-based proliferation suppression assay was performed
as described before [14]. In short, the freshly isolated Tresp were
labelled with CFSE (Molecular Probes Invitrogen, Breda, The
Netherlands). In a U-bottom 96-wells plate, 2*10
4 Tresps were
stimulated with soluble anti-CD3 (2.0 pg/mL, WT32 IgG2a
monoclonal antibody, kindly provided by dr. W Tax, Radboud
University Nijmegen Medical Centre, Nijmegen, The Nether-
lands) in the presence of 1*10
5 irradiated accessory cells. Tresp
were co-cultured for 5 days with varying amounts of Treg (Treg/
Tresp ratios 0/1, 0.25/1, 0.5/1, 1/1 or 2/1). All conditions were
performed in triplo in a final volume of 200 mL. Control
conditions were incorporated to validate the assay, including
monocultures of un-stimulated Tresp, and of stimulated accessory
cells, Treg, and surpluses of Tresp. After culture, cells were stained
with anti-CD4-APC and 7AAD (BD Biosciences, #559925), and
the CFSE signal of cells in the CD4
+7AAD
2 lymphogate was
analysed by flowcytometry on a FACS Canto II flowcytometer
(BD Biosciences). Data were analysed with FACS Diva software
version 6.1.2. (BD Biosciences). The amount of proliferation
achieved in the 0/1 ratio was set at 0% suppression. The median
relative amount of suppression in the Treg/Tresp co-cultures was
calculated. By linear interpolation, the inhibitor ratio (Treg/Tresp)
ratio at which 40% suppression of proliferation was achieved
(IR40) was calculated.
T cell phenotyping and cytokine analysis
Treg were defined as CD25
+FoxP3
+ CD4
+ T cells [20] and as
CD25
+CD127
2 CD4
+T cells [19]. Furthermore, CD45RA
expression was used to stratify CD25
+CD127
2 CD4
+ T cells for
memory (CD45RA
2) and naı ¨ve (CD45RA
+) Treg [21]. For
phenotyping, PBMC were stained with different combinations of
anti-CD3-horizon 450 (BD biosciences, #560365), anti-CD3-
PerCP (BD biosciences, #27355), anti-CD4-APC, anti-CD4-
PerCP (Biolegend, #300528), anti-CD25-PECy7 (BD Biosciences,
#54679), anti-CD45RA-PE (BD Biosciences, #07804), anti-
CD127-FITC or anti-FoxP3-PE (E-Bioscience, #12-4776), and
analysed on a FACS Canto II flowcytometer. The absolute
Vitamin D3 Supplementation and T Cells in MS
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counter (Beckman Coulter).
The cytokine profile of CD4
+ T cells was determined by
assessing the intracellular cytokine pattern of CD3
+CD8
2
lymphocytes, which are further referred to as CD4
+ T cells, by
flowcytometry [14]. PBMC were stimulated for 5 hours with
calcium ionomycine (Sigma Aldrich), PMA (Sigma Aldrich) and
cytokine excretion was blocked with monensin (BD Biosciences).
CD69 expression was included to assess the activation status of the
cells. Cells were stained intracellularly with anti-IL-4-PE (Biole-
gend, #500704), anti-IFN-c-FITC (BD Biosciences, #340449),
anti-IL-17A-PerCP-CY5.5 (Biolegend, #512314), anti-IL-10-APC
(Biolegend, #501410) and anti-CD69-PE-CY7 (Biolegend,
#310912), and extracellularly with anti-CD3-horizon 450 and
anti-CD8-APC-H7 (BD Biosciences, #641400). Samples were
analysed on a FACS Canto II flowcytometer.
Statistical analysis
Statistical analysis was conducted with SPSS version 15.0
software (SPSS inc., Chicago IL, USA) and figures were
constructed with GraphPad Prism 5 software (GraphPad
Software inc., La Jolla CA, USA). The median and correspond-
ing range (min – max) are provided for continuous variables.
Differences between two related samples (week 0 and 12) were
assessed with the Wilcoxon signed-ranks test, the Man Whitney U
Table 1. Patient characteristics.
Median/
Category
Min-Max
range/N (%)
Sex Female N=8 (53%)
Male N=7 (47%)
Age 35.15 year 25.47–49.36
MS duration since first symptoms 3.47 year 0.63–5.58
Time since last relapse 0.96 year 0.21–3.35
Number of relapses last 12 months 1.0 0.0–3.0
EDSS score* 2.0 0.5–4.0
Duration of IFN-b use 1.21 year 0.14–4.47
IFN-b type AvonexH N=3 (20%)
BetaferonH N=3 (20%)
RebifH N=9 (60%)
Race Caucasian N=14 (93%)
Hispanic N=1 (7%)
*Expanded Disability Status Scale [34].
doi:10.1371/journal.pone.0015235.t001
Figure 1. Vitamin D and calcium metabolism during supplementation. A–B) The serum levels of 25(OH)D (A) and 1,25(OH)2D (B) are shown
for the study visits at week 0, 2, 4, 6, and 12. The thick line indicates the median level, the grey zone the interquartile range. The thin lines show the
minimum and maximum values. C) Total serum calcium levels at all study visits (week 0, 2, 4, 6, 12, 16, and 24). Hypercalcaemia is designated as a
serum total calcium level $2.6 mmol/L. The grey lines indicate the median values. D) Urine levels of total calcium and creatinine levels and their ratio
at week 12 and 24. Hypercalciuria is designated as a urine total calcium/creatinine ratio .1.0 mmol/L*(mmol/L)
21. The lines indicate the median
values.
doi:10.1371/journal.pone.0015235.g001
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unless indicated otherwise. A p-value ,0.05 was considered
statistically significant.
Results
Adverse events and patient compliance
The characteristics of the 15 participants are shown in Table 1.
All patients completed the 12 week supplementation protocol
without side effects other than increased flatulence (N=1).
Patients reported some beneficial changes, including decreased
fatigue (N=8), decreased headache (N=2), decrease in eczem-
atous eruptions (N=1). During the 12 weeks of supplementation,
1 patient developed a relapse of MS, at week 7 of the protocol,
which was confirmed by the treating neurologist. This patient was
treated with pulsed prednisolone therapy. During the follow-up
period, 1 additional patient suffered from an MS relapse (week
19), resulting in a mean annualized relapse rate of 0.27 (SD 0.70)
over 24 weeks in this cohort, compared to 0.80 (SD 0.77) in the
year prior to this study (Mann Whitney U test P=0.014). No
further (serious) adverse events were registered. The median total
number of missed days of vitamin D3 intake was 0/84 days (0–5),
according to the patient’s diaries. Measurement of residue in the
returned vitamin D bottles revealed a median difference of 20.2/
42 mL (28.0–8.0) at week 6, and of +0.4/42 mL (27.5–5.0) at
week 12.
Biochemical assessment
Serum levels of 25(OH)D increased gradually during the study
in all patients (Figure 1A). The median level was 50 nmol/L (31–
175) at week 0, and the serum level 25(OH)D of 2 patients
exceeded 100 nmol/L (109 and 175 nmol/L, respectively).
Remarkably, the patient with the highest serum 25(OH)D level
used no vitamin supplements. At week 12, the median 25(OH)D
levels was 380 nmol/L (151–535) (P,0.001). Additionally, a rise
in serum 1,25(OH)2D levels was observed, which stabilized after 4
weeks (Figure 1B). After 6 weeks of supplementation, a decrease in
serum PTH was observed (Table 2). Serum uncorrected and
albumin corrected calcium levels were not significantly elevated,
and remained below 2.6 mmol/L in all subjects (Figure 1C).
Additionally, no hypercalciuria (urinary calcium to creatinine ratio
.1.0) was observed (Figure 1D). Liver enzyme tests remained
unaffected. However, serum creatinine levels gradually increased
during vitamin D3 supplementation, but remained stable during
the follow-up visits (Table 2).
Regulatory T cell numbers are not affected by vitamin D
supplementation
The difference in composition and function of the T cell
compartment between week 0 and week 12 was assessed in the 14
patients that remained relapse-free during the first 12 weeks. No
difference was observed in the absolute amount of T cells in the
circulation [1.37610
6 (0.91–2.39) vs. 1.32610
6 (0.90–2.24) cells/
Table 2. Biochemical follow-up.
Supplementation of vitamin D3 Follow-up after cessation
W0 W6 W12 W16 W24
Parameter Median
(Min–
Max) Median
(Min–
Max) P
B Median
(Min–
Max) P
B Median
(Min–
Max) P
B Median
(Min–
Max) P
B
25-hydroxyvitamin
D
50 31–175 285** 122–401 0.001 380** 151–535 0.001 - - - - - -
1,25-
dihydroxyvitamin
D
146 58–272 208** 99–434 0.002 202** 90–400 0.003 - - - - - -
Total calcium
(mmol/L)
2.3 (2.2–2.5) 2.4 (2.2–2.5) 0.133 2.4 (2.2–2.5) 0.208 2.4 (2.2–2.5) 0.176 2.4 (2.2–2.5) 0.337
Albumin (g/L) 39 (32–47) 39 (31–44) 0.134 39 (31–46) 0.606 39 (31–43) 0.284 38 (31–46) 0.546
Corrected calcium
(mmol/L)
A
2.36 (2.14–2.52) 2.38* (2.32–2.56) 0.048 2.42 (2.26–2.50) 0.082 2.40 (2.24–2.58) 0.069 2.38 (2.24–2.50) 0.396
Phosphorus
(mmol/L)
1.0 (0.7–1.1) 1.1 (0.8–1.4) 0.057 1.1** (0.9–1.5) 0.008 1.0* (0.8–1.4) 0.023 1.0 (0.8–1.3) 0.383
PTH (pmol/L) 4.6 (1.9–10.5) 2.8** (1.7–6.7) 0.003 - - - 3.5** (0.9–9.6) 0.003 3.3* (0.4–7.5) 0.003
Sodium (mmol/L) 139 (136–142) 139 (138–143) 0.150 141** (138–143) 0.005 140* (137–142) 0.048 140 (136–142) 0.080
Potassium
(mmol/L)
4.1 (3.4–4.6) 4.0 (3.5–4.6) 0.414 4.5** (3.6–4.7) 0.008 4.3 (3.6–4.7) 0.555 4.0 (3.7–4.3) 0.133
Urea (mmol/L) 3.5 (2.3–6.0) 3.5 (2.4–6.9) 0.776 3.7 (2.6–6.4) 0.221 3.8 (2.7–5.8) 0.073 3.9 (2.6–6.0) 0.055
Creatinine
(mmol/L)
65 (47–84) 69 (49–99) 0.060 73* (49–109) 0.018 74* (49–97) 0.012 73 (41–93) 0.064
AST (U/L) 31 (21–42) 32 (21–40) 0.820 - - - 29 (20–52) 0.955 28 (19–51) 0.955
ALT (U/L) 34 (19–95) 33 (22–80) 0.975 - - - 32 (19–120) 0.670 30 (17–48) 0.900
ALP (U/L) 67 (42–93) 62 (45–85) 0.529 - - - 69 (43–85) 0.950 68 (49–99) 0.442
ACalculated with the formula: Calciumcorr (mmol/L) = total Calcium (mmol/L)+ [(40 – Albumin (g/L))*0.02].
BDifference when compared to baseline levels was tested with the Wilcoxon Signed-Ranks test.
*P,0.050;
**P,0.010.
doi:10.1371/journal.pone.0015235.t002
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the proportions of circulating CD4
+ Treg cells (Figure 2A). Week 0
and week 12 proportions of CD25
+FoxP3
+ and CD25
+CD127
2
CD4
+ Treg did not differ significantly (Figure 2B–C). Proportions
of these two Treg phenotypes correlated well (Pearson R=0.891,
P,0.001; ICC=0.872, P,0.001), and 74.03% (52.09–89.75) of
CD25
+CD127
2 Treg was FoxP3
+. The expression of CD45RA
was used to stratify Treg for CD45RA
+ naı ¨ve and CD45RA
2
memory Treg (Figure 2A). There was no difference in the
circulating proportions of both naı ¨ve and memory Treg between
week 0 and week 12 (Figure 2D).
Modest non-significant improvement of regulatory T cell
suppressive function
The suppressive capacity of Treg was assessed ex-vivo in a
proliferation suppression assay. Of 1 patient, Tresp cells were
anergic to anti-CD3 stimulation at week 0. Of the remaining 13
patients, a proliferation suppression assay was acquired at week 0
and week 12. No difference was observed in the amount of Tresp
cell proliferation in the culture system [82.8% (53.9–93.3) vs.
83.4% (64.0–96.3); P=0.848]. At both time points, an increasing
suppression of Tresp proliferation was seen with increasing Treg/
Tresp ratio (Figure 3). At week 0, the median IR40 was at a Treg/
Tresp ratio of 0.79 (0.37–1.31). At week 12, the median IR40 was
at 0.48 (0.29–1.27) (Mann Whitney U test P=0.090). Although
Treg suppressive function tended to improve, this improvement
was not statistically significant (P=0.143). Baseline 25(OH)D
levels did not differ significantly between improving and non-
improving subjects (49 nmol/L (31–109) vs. 74 nmol/L (48–99),
respectively; P=0.260). However, non-improving subjects tended
to have better suppression at week 0 when compared to improving
subjects (IR40 0.51 (0.37–0.99) vs. 0.86 (0.49–1.31), respectively;
P=0.076).
CD4
+ T cell cytokine profile shifts from pro- to anti-
inflammatory
The cytokine profile of the CD4
+ T cells was assessed with an
intracellular FACS-staining (Figure 4A). Cytokines of interest were
IFN-c (Th1 cytokine), IL-17 (Th17 cytokine), IL-4 (Th2 cytokine)
and IL-10 (regulatory cytokine). The efficacy of stimulation, as
evaluated by the expression level of the activation marker CD69,
was comparable between week 0 and 12 (median MFI =91 030
Figure 2. Phenotypic analysis of circulating regulatory T cells (Treg). A) Isolated PBMC were analyzed directly ex-vivo by flow cytometry. In the
lymphogate, CD3
+CD4
+ cells were assessed for the proportions of CD25
+FoxP3
+ and CD25
+CD127
2 Treg cells. Expression of CD45RA was analyzed to
phenotypenaı ¨ve(CD45RA
+)andmemory (CD45RA
2)Treg.B–D)TheproportionsofcirculatingCD25
+FoxP3
+(B)andCD25
+CD127
2 (C)Treg,andofnaı ¨ve
Treg (D) before and after vitamin D3 supplementation (week 0 and 12). Significance was assessed with the Wilcoxon signed ranks comparison test.
doi:10.1371/journal.pone.0015235.g002
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week 0 and 12 were compared, no significant difference was
observed in the proportions of CD4
+ T cells positive for IFN- c
[7.82% (3.45–12.74) vs. 6.51% (1.07–14.66)], IL-17 [0.90% (0.50–
2.09) vs. 0.85% (0.16–2.19)], or IL-4 (2.04% (0.80–3.62) vs. 2.37%
(0.88–4.21)]. However, the proportion of IL-10
+ CD4
+ T cells was
significantly increased [0.36% (0.20–0.95) vs. 0.69% (0.13–1.14);
P=0.021] (Figure 4B). When the Th1/Th2 balance was assessed,
we found that the IFN-c
+/IL-4
+ balance was decreased after
supplementation [3.68 (1.86–10.76) vs. 2.98 (0.71–5.55); P=0.035]
(Figure 4B).
Discussion
In this study, the effects of high dose vitamin D3 supplementation
on safety and T cell parameters in patients with RRMS were
assessed. We observed that supplementation of 20 000 IU/d
vitamin D3 for 12 weeks was without negative side-effects and
without decompensation of calcium metabolism (i.e. hypercalcae-
mia and hypercalciuria). The number of Treg remained unaffected,
as well as the numbers of Treg memory and naı ¨ve subtypes. Results
regarding Treg suppressive capacity were inconclusive. However, a
shift was observed in the cytokine profiles of CD4
+T cells, with an
increased circulating proportion of IL-10
+ CD4
+ T cells, and a
decreased ratio of Th1/Th2 cells (IFN-c
+/IL-4
+ CD4
+ T cell ratio).
These results further add to the notion that vitamin D is a
physiological immune modulator in vivo. Monitoring the cytokine
profile of CD4+ T cells could be a valuable tool to assess the
immunological efficacy of vitamin D3 in randomized controlled
clinical trials on vitamin D supplementation in patients with MS.
This study confirmed that supplementation of high doses vitamin
D3 does not induce a decompensation of calcium metabolism in
patients with MS [12,18]. Without a dose-escalation supplementa-
tion scheme, we did not detect hypercalcaemia or hypercalciuria.
The slight non-significant increase in serum calcium and phos-
phorus most likely reflects a correction of vitamin D insufficiency in
this cohort. A gradual increase in serum creatinine levels was
observed during vitamin D3 supplementation, which however
remained below 110 mmol/L in all patients. The dramatic
complication of a hypercalcaemia associated decrease of glomerular
filtration rate (GFR) is unlikely, since neither hypercalcaemia nor
hypercalciuria was detected. Earlier dose-escalation trials supple-
menting up to 280 000 IU/w for 28 weeks and up to 40 000 IU for
52 weeks did not report either significant elevations of serum
Figure 3. Regulatory T cell suppressive function. A) A representative example of the CFSE signal in the CD4
+7AAD
2 lymphogate. The upper
panel (0.00) shows proliferation of Tresp cells without Treg. Co-culture with an increasing proportion of Treg results in an inhibition of Tresp cell
proliferation (downward panels, ratio 0.25:1, 0.5:1, 1:1 and 2:1, respectively). An increasing proportion of CFSE
2 Treg can be observed, and a
subsequent decrease of proliferating CFSE
+ Tresp cells. Between the Treg/Tresp ratio 0.25 and 2.0, all patients achieved at both time points (week 0
and 12) 40% suppression of proliferation (IR40). B) The box and whisker plots show the suppression at each Treg/Tresp ratio before (week 0, open
boxes) and after supplementation (week 12, dashed boxes). The boxes show the interquartile range, the whiskers the minimum and maximum value.
C) IR40 before and after vitamin D3 supplementation (week 0 and 12).
doi:10.1371/journal.pone.0015235.g003
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ingly, however, earlier reports described a rise in serum creatinine
which was not accompanied by a decreased GFR in patients treated
with 1,25(OH)2Do r1 a(OH)D [22]. Physiologically, 25(OH)D is
filtrated in complex with vitamin D binding protein (DBP) by the
glomeruli and re-absorbed by proximal tubular epithelial cells [23].
Interestingly, creatinine is being secreted in the proximal renal
tubuli as well. We postulate that a massive increase of 25(OH)D-
DBP complex reabsorbtion competes with tubular creatinine
excretion and hereby increases serum creatinine levels. Although
we believe that the increased serum creatinine levels do not reflect a
decreased GFR, future studies on massive dose vitamin D
supplementation should be cautious towards patients with an
impaired kidney function. On the whole, biochemical data show the
absence of vitamin D3 toxicity in participants of this study.
We found no effect of vitamin D supplementation on the
number of Treg in the circulation. In MS, the function rather than
the number of Treg has been reported to be impaired [24,25], and
to relate with serum 25(OH)D levels [14]. Additionally, other
immune modulating therapies also have been shown to improve
Treg function rather than Treg numbers [26,27]. An expansion of
naı ¨ve Treg has been described in Glatiramer Acetate treatment
[26], and a decrease of memory Treg cells in IFN-b treatment
[27]. Therefore, we also assessed these Treg subsets, but found no
Figure 4. T helper cell cytokine profiles. A) One million PBMC were stimulated for 5 hours with PMA and calcium ionomycin in the presence of
monensin, and subsequently stained for flow cytometric analysis. In the lymphogate, CD3
+CD8
2 cells were assessed for the proportions of IFN-c
+, IL-4
+,
IL-17
+ andIL-10
+ cells.CD69 was included to evaluateactivation. B) Theproportions of IL-10
+ CD4
+ T cells before andafter supplementation. C) Theratio
between Th1 (IFN-c
+) and Th2 (IL-4
+) cells before andafter supplementation. Significancewas assessed with the Wilcoxon signed ranks comparison test.
doi:10.1371/journal.pone.0015235.g004
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and memory Treg.
Previously, we observed a correlation of Treg suppressive
capacity with serum 25(OH)D levels [14]. Although Treg
suppressive function was improved in several patients after 12
weeks of vitamin D3 supplementation, this improvement was not
statistically significant. The size of the cohort assessed is most likely
too small to detect a possible effect in this complex assay.
Alternatively, one could speculate from our previous work that
only in the patients with the poorest vitamin D statuses, an
improved suppression can be expected [14]. Although vitamin D
statuses at week 0 were lower in the 9 improving patients when
compared to the 4 non-improving patients, the difference was not
significant. Additionally, Treg suppressive function is not impaired
in all RRMS patients, and shows a substantial overlap with
healthy individuals [25–28]. Therefore, it can be speculated that
an adequate Treg function cannot be improved further on vitamin
D3 supplementation. Indeed, the patients of whom Treg
suppressive function improved tended to have a poorer suppres-
sion at week 0. Lastly, the genetic background of an individual
may affect the immunological response to vitamin D3 supplemen-
tation [29]. Altogether, the data collected in this study regarding
Treg suppressive function remain inconclusive.
A significant effect on the composition of the T helper cell
compartment was detected. The ratio of IFN-c
+/IL-4
+ CD4
+ T
cells represents the balance between pro-inflammatory Th1 and
anti-inflammatory Th2 cells, and is regarded an important variable
in autoimmune diseases [30]. During supplementation, this ratio
changed towards a less pro-inflammatory profile. The effect on
absolute proportions of IFN-c
+ and IL-4
+ CD4
+ T cells may be too
small to be detected in this small cohort. This is in accordance with
previous cross-sectional findings [14]. Interestingly,we detected also
more IL-10
+ CD4
+ T cells after supplementation. The source of
IL10
+ cells in the CD4
+ T cell compartment may be the T
regulatory cell type 1 (Tr1) [31]. Alternatively, IL-10 has also been
proposed to be a typical Th2 cytokine. However, we measured no
double producers of IL-10 and the (other) typical Th2 cytokine IL-4
(data not shown). Therefore, we speculate that the rise in IL-10
+
CD4
+ T cells might reflect expansion of inducible regulatory Tr1
cells. The findingof an altered profile of pro- and anti-inflammatory
CD4
+ T cells conforms to observations in experimental studies [5]
and further supports the assessment of vitamin D3 as a natural
immune modulator in MS [3].
Although the present study did not comprise a placebo-group, it
delivered valuable new information. We earlier performed a cross-
sectional study, in which serum 25(OH)D levels correlated with
peripheral T cell homeostasis [14]. However, the cross-sectional
design did not allow statements on causality, since physical
exercise and UV exposure per se could be the real underlying
mediators [32]. Our current study revealed 25(OH)D as a good
causal candidate. Ultimately, however, placebo controlled studies
should demonstrate that vitamin D3 is an immune modulator in
vivo. Regarding these upcoming trials, it is also of interest that we
included patients treated with immune modulating drugs (IFN-b).
Interestingly, therapy with 1,25(OH)2D showed synergistic effects
with IFN-b in an EAE model of MS [33]. Upcoming clinical trials
will most likely assess add-on effects of vitamin D3 on current
immune modulating drugs. Results from the present study suggest
that it is worthwhile to combine immune-modulating drugs like
IFN-b with vitamin D3 in order to further modulate the immune
system in a for MS beneficial way.
In conclusion, we showed in a cohort of RRMS patients that
supplementation of high doses vitamin D3 did not result in a
decompensated calcium metabolism. Additionally, vitamin D3
appeared to skew the CD4
+ T cell compartment to a more
pronounced anti-inflammatory state. Herewith, we confirmed that
the peripheral CD4
+ T cell compartment cytokine profile is a
potential outcome measure in upcoming randomized controlled
clinical trials. Ultimately, these trials should demonstrate whether
vitamin D3 isan immuneanddisease modulatingcompound in MS.
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